Loss Narrows for Elan

 

The return of Tysabri will be the key factor in Elan's(ELN) performance this year, the company said Tuesday, but it didn't offer a specific sales prediction for the multiple sclerosis drug.

Last summer, Tysabri was reintroduced in the U.S. and launched in several European Union countries, 18 months after Elan and its partner Biogen Idec(BIIB) suspended it from the U.S. market following a suspected link to a potentially deadly brain disorder.

Shane Cook, Elan's chief financial officer, said the Ireland-based company is "confident [Tysabri] will be a blockbuster drug in MS."

Those comments came as Elan posted a fourth-quarter loss of $26.5 million, or 6 cents a share, on revenue of $166.4 million. For the same period in 2005, Elan lost $58.3 million, or 14 cents a share, and had revenue of $140.4 million. Tysabri produced a combined $30 million in fourth-quarter sales and $38.1 million for 2006.

"Our financial performance [in 2006] improved and our pipeline portfolio continued to progress," said Kelly Martin, Elan's president and CEO.

Tysabri aside, Elan predicted total sales will exceed $500 million in 2007 for product revenue, manufacturing revenue, royalties and contract revenue. Last year's top line was $560.4 million, including Elan's share of Tysabri's sales.

Even though Elan declined to give a sales forecast for the drug for this year, "on the basis of the initial take-up," the company believes growth in Tysabri revenue will drive its return to profitability.

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,890.46 1,351.95 2,927.23 20.47
Oil *
118.75
UP
6.51
UP
1.99
UP
11.37
UP
0.72
10 Yr
2.05%
SPDR Gold
168.02
+0.05%
+0.15%
+0.39%
+3.65%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet